GlobeImmune files for $69 million IPO to fund cancer/infection immunotherapies
This article was originally published in Scrip
Executive Summary
GlobeImmune wants to raise $69 million in an initial public offering to fund development of its oncology and infectious disease immunotherapies before it runs out of cash around the end of 2012. The company did not indicate how many shares it will sell, or at what price.